Enzi-Kennedy FDA Bill (DrugWonks.com)
In his entry, blogger Robert Goldberg expresses concerns about a New York Times article in which Gardiner Harris "depicted the Enzi-Kennedy FDA bill as a throwback to slow paper gathering approaches to drug safety without regard to 21st century science or proposals to accelerate a response to the more expensive and prevalent 'side effects' of having a disease like Alzheimer's without effective treatments." Goldberg writes about the bill, the Critical Path Initiative, and the way in which Harris' article overlooked some key components of the issue.
Up the Drug Approval Process? (Eye on FDA)
Will the drug approval process be expedited? In his entry, blogger Mark Senak discusses recent congressional action regarding this issue.